Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Arun J. Mohan is a member of the Intellectual Property Group. He focuses his practice on Hatch-Waxman and biosimilar patent litigation.
Before joining Schiff Hardin, Arun was an intellectual property litigation associate at a Wilmington, Del. law firm. He was a clinical research associate for a global contract research organization before attending law school.
Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.
The Supreme Court recently agreed to hear a challenge to the current interpretation of the venue statute in patent infringement cases.
The Corporate & Securities Law Advisor